Table 2: Summary of findings table.
Outcomes |
Anticipated absolute effects*(95% CI) |
Relative effect |
No of participants |
Certainty of the evidence |
|
Risk with placebo or no RhIG |
Risk with RhIG provision |
||||
Iso-immunization in subsequent pregnancy |
13 per 1,000 |
10 per 1,000 |
OR 0.75 |
250 |
⨁◯◯◯ |
Antibody formation detected six-month after initial pregnancy by indirect combs test |
31 per 1,000 |
13 per 1,000 |
OR 0.41 |
194 |
⨁◯◯◯ |
Increased fetal surveillance or fetal transfusion in subsequent pregnancy. |
not pooled |
not pooled |
not pooled |
(0 studies) |
- |
Neonatal morbidity (Jaundice, neonatal anemia, erythroblastosis or bilirubin encephalopathy in subsequent pregnancies) |
not pooled |
not pooled |
not pooled |
(0 studies) |
- |
Maternal adverse events of ant-D administration including anaphylaxis |
not pooled |
not pooled |
not pooled |
(0 studies) |
- |
Cost of treatment |
not pooled |
not pooled |
not pooled |
(0 studies) |
- |
aBoth included studies were considered as high risk of bias; bThis outcome is a surrogate for clinically relevant outcome; cThere is a wide confidence interval crossing line of no effect.